RecruitingPhase 3

Cardioprotection on Chemotherapy-Induced Cardiotoxicity

Egypt30 participantsStarted 2023-07-18

Plain-language summary

The aim of the present study is to evaluate the protective impact of cardioprotective medications on the chemotherapy- induced cardiotoxicity.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Willingness of the legal representative of research participant to participate in the study by giving "informed consent." * Ability to take oral medication. * Age 2-18 years at the time of diagnosis. Exclusion Criteria: * Documented allergy to cardioprotective medications

What they're measuring

Change in Left Ventricular Ejection Fraction (LVEF)

Timeframe: LVEF will be measured at Baseline and at the end of Induction Phase (42 Days)

Trial details

NCT IDNCT06853951

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-30

Contact for this trial

Christen Said

+201093942389 keristin.nazir21@pharma.asu.edu.eg

View on ClinicalTrials.gov More Cardiotoxicity trials